4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lungs ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.29318200199498556 | N/A |
Market Cap | $87.96M | N/A |
Shares Outstanding | 300.01M | 1.87% |
Employees | 131.00 | N/A |
Shareholder Equity | 71.46M | 20.08% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -2.93 | N/A |
P/S Ratio | 462.49 | N/A |
P/B Ratio | 1.23 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.2967 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $190.18K | N/A |
Earnings | -$21.20M | N/A |
EPS | -0.1 | N/A |
Earnings Yield | -0.3411 | N/A |
Gross Margin | 0.879 | N/A |
Operating Margin | -159.49 | N/A |
Net income margin | -111.49 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $62.63M | N/A |
Total Debt | $3.46M | N/A |
Cash on Hand | $46.89M | N/A |
Debt to Equity | 0.2024 | 20.75% |
Cash to Debt | $13.54 | 65.27% |
Current Ratio | $4.60 | -25.28% |